Accéder au contenu
Merck

SML2304

Clozapine N-oxide hydrochloride

≥98% (HPLC), powder, muscarinic DREADD activator

Synonyme(s) :

Clozapine N-oxide hydrochloride, 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e](1,4)diazepine N-oxide, hydrochloride salt

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

A propos de cet article

Formule empirique (notation de Hill) :
C18H19ClN4O · xHCl
Numéro CAS:
34233-69-7
Poids moléculaire :
342.82 (free base basis)
UNSPSC Code:
12352119
NACRES:
NA.77
Assay:
≥98% (HPLC)
Form:
powder
Storage condition:
desiccated

Principaux documents

Voir toute la documentation
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider

Nom du produit

Clozapine N-oxide hydrochloride, ≥98% (HPLC), Water soluble Clozapine N-oxide

SMILES string

ClC1=CC2=C(NC(C=CC=C3)=C3C(N4CC[N+]([O-])(C)CC4)=N2)C=C1.[xHCl]

InChI

1S/C18H19ClN4O/c1-23(24)10-8-22(9-11-23)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18/h2-7,12,20H,8-11H2,1H3

InChI key

OGUCZBIQSYYWEF-UHFFFAOYSA-N

biological source

synthetic

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

solubility

DMSO: 40 mg/mL, water: 40 mg/mL

shipped in

ambient

storage temp.

2-8°C

Catégories apparentées

General description

Clozapine N-oxide hydrochloride is a water soluble form of Clozapine N-oxide (CNO) (Sigma cat# C0832). CNO is a pharmacologically inert metabolite of the atypical anti-psychotic drug clozapine. CNO is a ligand for the engineered Gq protein coupled receptors (GPCRs) in the chemogenetic Designer Receptors Exclusively Activated by Designer Drug (DREADD). The typical use of DREADD is testing, enhancing neuronal firing and activating Gq signaling in neuronal and non-neuronal cells.

The selective targeting of DREADD systems to cell population can be achieved by using a cell type-specific promoter to drive DREADD expression, and the expression of this promoter can be further controlled using a recombinase-based system. DREADDs possess a low affinity for endogenous ligands and little constitutive activity, but may be activated by synthetic compounds such as CNO.

DREADD systems are activated by low nM concentrations of CNO and mobilize intracellular calcium. CNO appears to be pharmacologically and behaviorally inert in mice and rats when administered at the recommended doses (generally 0.1–3 mg/kg). CNO is commonly administrated via injection but also can be mixed into food chow or drinking water.

Other Notes

This is not a pharmaceutical grade product.

pictograms

Skull and crossbones
GHS06

signalword

Danger

hcodes

H301,H336

Hazard Classifications

Acute Tox. 3 Oral - STOT SE 3

target_organs

Central nervous system

Classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number
0000463730
0000463730
0000403012
0000403012
0000347116

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Rechercher un(e) COA

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Jean-Marc Guettier et al.
Proceedings of the National Academy of Sciences of the United States of America, 106(45), 19197-19202 (2009-10-28)
Impaired functioning of pancreatic beta cells is a key hallmark of type 2 diabetes. beta cell function is modulated by the actions of different classes of heterotrimeric G proteins. The functional consequences of activating specific beta cell G protein signaling
Georgia M Alexander et al.
Neuron, 63(1), 27-39 (2009-07-18)
Examining the behavioral consequences of selective CNS neuronal activation is a powerful tool for elucidating mammalian brain function in health and disease. Newly developed genetic, pharmacological, and optical tools allow activation of neurons with exquisite spatiotemporal resolution; however, the inaccessibility
Daniel J Urban et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 41(5), 1404-1415 (2015-09-19)
Elucidating how the brain's serotonergic network mediates diverse behavioral actions over both relatively short (minutes-hours) and long period of time (days-weeks) remains a major challenge for neuroscience. Our relative ignorance is largely due to the lack of technologies with robustness
Hu Zhu et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 39(8), 1880-1892 (2014-02-15)
Synaptic consolidation is a process thought to consolidate memory in the brain. Although lesion studies have mainly implicated the hippocampus (HPC) in this process, it is unknown which cell type(s) or regions of the HPC might be essential for synaptic
Susan M Ferguson et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 33(28), 11668-11676 (2013-07-12)
The dorsal striatum has been implicated in reward-based decision making, but the role played by specific striatal circuits in these processes is essentially unknown. Using cell phenotype-specific viral vectors to express engineered G-protein-coupled DREADD (designer receptors exclusively activated by designer
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique